Erasca, Inc. Income Statement
ERAS / Health Care|5 years of annual SEC 10-K data (FY2020-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| SG&A Expense | $41.7M | $37.7M | $33.0M | $22.6M | $8.0M |
| R&D Expense | $115.4M | $103.8M | $112.5M | $73.9M | $29.6M |
| Operating Income | -$179.6M | -$141.5M | -$247.4M | -$124.9M | -$109.3M |
| Net Income | -$161.7M | -$125.0M | -$242.8M | -$122.8M | -$101.7M |
| EPS (Basic) | -$0.69 | -$0.83 | -$1.99 | -$1.85 | - |
| EPS (Diluted) | -$0.69 | -$0.83 | -$1.99 | -$1.85 | - |
| Shares Outstanding | 233.8M | 150.2M | 122.0M | 66.3M | 21.0M |